Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Q's

1. Will we continue to see monthly revenues and expenses for TPL? Will the January report reflect the HTC settlement? And will future TPL revenues from their "half" of licensing efforts through Alliacense be reflected in these reports?

2. I am assuming that PTSC received their "list" to work with before allowing the approval of the BK Plan to go forward without objection. Is that too much of an assumption?

3. On this subject of splitting the potential licensees up .... surely this doesn't mean that we forego any license revenue from the companies TPL/Alliacense signs ... and we only get what we sign from our list?

TIA

Share
New Message
Please login to post a reply